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ABSTRACT
The causative agent of tuberculosis (TB) is Mycobacterium tuberculosis, which mainly infects lungs and causes severe, fever, weight loss, chest pain, 
etc. It is an extremely transmittable disease spreaded throughout the world as per the WHO. It has emerged as new threat and drug resistance strains 
of Mycobacterium are emerging throws a challenge to human’s health like Covid-19 in current scenario. TB is now come in the form of bone TB, which 
is very difficult to diagnosis due to very slow-growing characteristics of Mycobacterium. This review highlights the history, drug development, current 
treatment both allopathic and Ayurvedic, as well as novel drugs available for the treatment of drug resistance Mycobacterium.
Keywords: Tuberculosis, Nix-tuberculosis, Extensively drug-resistant-tuberculosis, Mycobacterium tuberculosis, Ayurvedic.
INTRODUCTION
In 1882, Dr. Robert Koch has discovered Mycobacterium tuberculosis 
which causes tuberculosis (TB). Mycobacteria are transition forms 
between bacteria and fungi. These bacteria are non-motile and non-
sporulating rods that resist decolorization with acidified organic 
solvents, that is, acid fast bacteria. The treatment for TB is linked with 
noncompliance to therapy because it consists of long-term treatment 
with a multidrug combination and is associated with the appearance of 
several side effects [1-3].
HISTORY AND DRUG DEVELOPMENT OF TB
The history of TB starts from early 1902 with discovery of para-
aminosalicylic acid. The drug development of drugs against TB is shown 
in Figs. 1 and 2. [4-8].
EPIDEMIOLOGY
About one-fourth of the world’s population is infected through TB. In 
2018, an estimated 26.9 million new TB cases occurred worldwide. 
Most new cases reported in Southeast Asia (45%), Africa (25%), and 
the Western Pacific (17%). In 2019, total 1,725,920 cases reported 
in India, in which the most infected states are Uttar Pradesh, Madhya 
Pradesh, Maharashtra, Gujarat, Delhi, Bihar, and Andhra Pradesh. 
ETIOLOGY
The main causative agent of TB is M. tuberculosis. Other similar 
causative agents are Mycobacterium bovis, Mycobacterium africanum, 
and Mycobacterium microti. TB infection occurs exclusively due to 
the breathing of airborne particles holding M. tuberculosis. Particles 
disperse primarily through coughing, sneezing, talking, etc., of patients 
with pulmonary infection or whose sputum possess a considerable 
number of bacteria are mainly infectious due to the presence of large 
number of bacteria [9,10].
Tubercle bacilli droplet nuclei having diameter <5 μ may stay suspended 
in air currents of room for several hours and increases the risk of spread. 
Although when these droplets settle down on surface of floor, it is hard 
to resuspend the bacteria due to its too large size. Contact with fomites 
(e.g., contaminated surfaces, food, and personal respirators) does not 
appear to facilitate spread. Environment also plays an important role 
in transmission of tubercle bacilli and this is increased by regular 
contact to patients, in the crowded area spreading large numbers of 
bacilli, poorly ventilated enclosed spaces are particular at high risk. 
Health-care practitioners who have close contact with active cases have 
increased risk.
TREATMENT
Single drug is not effective for the treatment of TB due to the emergence 
of drug-resistant bacteria. Therefore, recent treatment includes the 
combination therapy described below. The mechanism of action of anti-
tubercular drugs is shown in Fig. 2 [11,12].
COMBINATION THERAPY
1. Multidrug-resistant TB: Isoniazid and rifampicin-resistant 
M. tuberculosis strains can be treated by Cornerstone medicines.
2. Extensively drug-resistant-TB (XDR-TB): Fluoroquinolone and 
capreomycin, kanamycin, and amikacin resistance M. tuberculosis 
can be treated with XDR-TB along with multidrug resistance therapy.
3. Nix-TB: The long treatment duration of TB is the key cause of the 
emergence of drug-resistant bacteria. Therefore, it is a trial to 
make the treatment shorter, oral, and affordable doses which do not 
require drug at injectable form. It is a combination of pretomanid, 
bedaquiline, and linezolid. 
RECENT ADVANCEMENT
a) Bedaquiline: Chemically, it is a diarylquinoline inhibits mycobacterial 
adenosine triphosphate (ATP) synthase leads to intracellular ATP 
diminution [13]. It works on both aggressively replicating as well as 
dormant mycobacteria, which maintains ATP synthase activity [14]. 
b) Delamanid: It is metronidazole and nitroimidazopyran (nitro-
dihydro-imidazooxazole, 6-nitro-2,3-dihydroimidazo(2,1-b) oxazole) 
derivative. It is a pro-drug, requires activation, and acts by inhibiting 
the biosynthesis of mycolic acid.
c) Pretomanid: This drug is a pro-drug and requires intracellular 
activation by a F420-dependent glucose-6-phosphate-dehydrogenase 
pathway. Activation produces a des-nitro metabolite that generates 
reactive nitrogen species, leading to a decrease in intracellular ATP 
and anaerobic killing [15,16]. 
d) Sutezolid: It is a linezolid analog and has better in vivo activity with 
less toxicity in comparison with linezolid [17].
e) AZD5847: Like linezolid, AZD5847 is an oxazolidinone that inhibits 
mycobacterial protein synthesis by binding to the 50S ribosomal 
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subunit; it’s in vitro bactericidal activity is superior to that of 
linezolid [18]. 
f) SQ109: Structurally related to ethambutol,  SQ109 is a 
1,2-ethylenediamine with a different mechanism of action. It targets 
the transmembrane transporter encoded by the mmpL3 gene, SQ109 
interferes with cell wall assembly [19].
g) The nitroimidazoles: OPC-67683 (Delamanid) and PA-824 are under 
development as potential TB drugs.
h) AZD5847: AZD5847 is a potential new TB drug being developed 
by AstraZeneca. In December 2012, it was announced that the first 
patient had been enrolled in a Phase 2a trial of the drug in South 
Africa to assess the effectiveness of the drug for patients with TB, 
including patients with TB and HIV infection.
i) The fluoroquinolones: Moxifloxacin and gatifloxacin are currently 
being developed for the treatment of drug-sensitive TB.
j) TB drug combinations: The combination of moxifloxacin and 
pyrazinamide had the greatest early bactericidal activity. One 
advantage of this drug combination is that it does not involve either 
isoniazid or rifampicin. It is, therefore, suitable for use with patients 
who are resistant to these drugs. A regimen without rifampicin 
would greatly simplify the provision of TB treatment alongside HIV 
antiretroviral therapy [20-44].
There are various side effects in TB drugs such as itchy skin, bruising or 
yellow skin, skin rashes, stomach upset, nausea, vomiting, diarrhea or 
loss of appetite, lack of feeling or tingling in the hands or feet, changes 
in your eyesight, particularly changes in red or green color vision, dark 
colored urine, and yellow eyes. Although several drugs are in the market, 
thrust of new drug is always there, so an alternate Ayurvedic drug 
therapy was developed in the treatment of TB due to side effects [45-54].
Fig. 1: History and drug development of anti-tubercular drugs
Fig. 2: Mechanism of action of anti-tubercular drugs
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AYURVEDIC DRUGS USED IN TB
In Ayurveda, TB is known as Kshayaroga or Rajyakshma. Ayurvedic 
treatment procedures that are recommended for TB include Snehana 
which means oleation. It basically involves massage with warm 
medicated oils infused with the properties of herbs to treat the 
aggravated doshas and helps in liquefying and dislodging toxins from 
the smallest channels of the body, Swedana which means sudation or 
sweat therapy (it is three types, Tapa, that is, fomentation, involves 
the use of a metal object, heated cloth or warm hands to provide heat 
to the body, Upanaha involves the use of a hot poultice consisting of 
various herbs based on the aggravated dosha, Ushma refers to the use 
of warm steam created by boiling the appropriate herbs depending 
on the dosha that need to be balanced, and Dhara involves pouring of 
warm medicated liquid over the body), Vamana which means medical 
emesis and Virechana which means purgation (commonly used herbs 
for virechana are senna, aloe, and rhubarb).
Although, these procedures are only effective in individuals with 
aggravated doshas and in those who are strong enough to tolerate these 
therapies. Shodhana karma which means purification therapies, which 
should not be used in weak individuals, and they should be very mild 
even when used in strong individuals with TB. This is because there 
is kshaya which means depletion of all seven dhatus in TB. Hence, 
nourishing the treatment should be given to strengthen the body. 
However, care should be taken that dhatu agni is not affected [55-59]. 
Various drugs used in TB are as following:
Ayurvedic drugs used in TB are as – Acalypha indica (family – 
Euphorbiaceae) commonly known as Kuppi, Adhatoda vasica 
(family – Acanthaceae) commonly known as Vaasa, Allium cepa 
(family – Liliaceae) commonly known as Palaandu, Allium sativum 
(family – Liliaceae) commonly known as Lashuna, Aloe vera (family 
– Liliaceae) commonly known as Ghritkumaarika, Vitex negundo 
(family – Verbenaceae) commonly known as Nirgundi, Trichosanthes 
dioica (family – Cucurbitaceae) commonly known as Patola, Tinospora 
cordifolia (family – Menispermaceae) commonly known as Guduuchi, 
Caesalpinia pulcherrima (family – Caesalpiniaceae) commonly 
known as Padangam, Prunus armeniaca (family – Rosaceae) commonly 
known as Peetaalu, Ocimum sanctum (family – Labiatae) commonly 
known as Tulasi, Morinda citrifolia (family – Rubiaceae) commonly 
known as Ashyuka, Myrtus communis (family – Myrtaceae) commonly 
known as Muurad-daan, Canscora decussata (family – Gentianaceae) 
commonly known as Daakuni, Piper species (family – Piperaceae) 
commonly known as Pippali, Vitex trifolia (family – Verbenaceae) 
commonly known as Sinduvaara, Mallotus philippensis (family – 
Euphorbiaceae) commonly known as Kampillaka, Colebrookea 
oppositifolia (family – Lamiaceae) commonly  known as Binda, Rumex 
hastatus (family – Polygonaceae) commonly known as Katambal, 
Mimosa pudica (family – Mimosaceae) commonly known as Laajavanti, 
and Kalanchoe integra (family – Crassulaceae) commonly known as 
Parnabija.
Medicines that are described in Ayurveda for the management of TB 
are Eladi churna, Sitopaladi churna, Chitraka Haritaki, Mahalaxmivilasa 
Rasa, Chyawanprashavaleha, Draksharishta, Dhanvantara Gutika, 
Bhringrajasava, Swarna Malini, Vasanta, Madhumalini Vasanta, and 
Vasanta Kusumakar [60-73].
CONCLUSION
In today’s world, there has been an increase in demand of 
phytopharmaceuticals in all over the world because more side effects 
of allopathic drugs. The main aim of this review article is to compile 
various anti-tubercular drugs of both allopathic as well as Ayurvedic 
sources. 
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